CBAY(Delisted)
Cymabay Therapeutics·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CBAY
Cymabay Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing therapies for liver and other chronic diseases
7575 Gateway Blvd, Suite 110, Newark, CA 94560
--
Cymabay Therapeutics, Inc., was incorporated on October 5, 1988 under the laws of the State of Delaware. CymaBay Therapeutics focuses on the development of therapies for the treatment of metabolism and rare diseases with high demand. Its lead product candidate, Arhalofenate, is currently being developed for the treatment of gout. Arhalofenate has successfully completed Phase 3 clinical trials in gout patients and patients who consistently demonstrate the ability to reduce gout attacks and lower serum uric acid.
Company Financials
EPS
CBAY has released its 2023 Q4 earnings. EPS was reported at -0.35, versus the expected -0.31, missing expectations. The chart below visualizes how CBAY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CBAY has released its 2023 Q4 earnings report, with revenue of 57.00K, reflecting a YoY change of NaN%, and net profit of -41.90M, showing a YoY change of -57.33%. The Sankey diagram below clearly presents CBAY's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
